The tumour samples were selected to give a distribution of point mutations and premature termination codons (PTCs) throughout the 3 coding exons of VHL (Table I) with samples from 56 patients containing 52 unique VHL mutations or polymorphisms (Table IA–C) together with a further 28 tumours (24 ccRCC and 4 other subtypes) in which no variant had been identified. Here, VHL is linked to neoplasm.